Predictive and Prognostic Value of Non-Coding RNA in Breast Cancer
1
Section of Epidemiology and Population Sciences, Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA
2
Institute of Experimental Immunology, University of Zurich, CH-8057 Zurich, Switzerland
3
Molecular Imaging Program at Stanford, Department of Radiology, Stanford University, Stanford, CA 94305, USA
4
Thunder Biotech, 395 Cougar Blvd, Provo, UT 84604, USA
5
Department of Morphology, Embryology and Medical Oncology, Università Degli Studi di Ferrara, 44100 Ferrara, Italy
6
Department of Biology & Biochemistry, University of Bath, Bath BA27AY, UK
7
Department of Medical Surgery and Health Sciences, University of Trieste, 34127 Trieste, Italy
*
Author to whom correspondence should be addressed.
Academic Editor: Stephen H. Safe
Cancers 2022, 14(12), 2952; https://doi.org/10.3390/cancers14122952
Received: 22 May 2022
/
Revised: 9 June 2022
/
Accepted: 14 June 2022
/
Published: 15 June 2022
(This article belongs to the Special Issue The Molecular Predictive and Prognostic Biomarkers in Breast Cancer)
Simple Summary
In our journey to fight cancer, biomarkers for prediction and efficacy of therapies could help medical practitioners to give patients the best available treatments in a timely fashion. Non-coding RNA, in most recent times, has been shown to play crucial roles for cancer growth. An exponential increase of evidence in the clinical literature supports their implication to predict patients’ outcomes. In this article, we summarize the current predictive and prognostic value of non-coding RNA in breast cancer.
For decades since the central dogma, cancer biology research has been focusing on the involvement of genes encoding proteins. It has been not until more recent times that a new molecular class has been discovered, named non-coding RNA (ncRNA), which has been shown to play crucial roles in shaping the activity of cells. An extraordinary number of studies has shown that ncRNAs represent an extensive and prevalent group of RNAs, including both oncogenic or tumor suppressive molecules. Henceforth, various clinical trials involving ncRNAs as extraordinary biomarkers or therapies have started to emerge. In this review, we will focus on the prognostic and diagnostic role of ncRNAs for breast cancer.
View Full-Text
Keywords:
non-coding RNA; biomarkers; breast cancer; prognostic; diagnostic
▼
Show Figures
Figure 1
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
MDPI and ACS Style
Sobhani, N.; Chahwan, R.; Roudi, R.; Morris, R.; Volinia, S.; Chai, D.; D’Angelo, A.; Generali, D. Predictive and Prognostic Value of Non-Coding RNA in Breast Cancer. Cancers 2022, 14, 2952. https://doi.org/10.3390/cancers14122952
AMA Style
Sobhani N, Chahwan R, Roudi R, Morris R, Volinia S, Chai D, D’Angelo A, Generali D. Predictive and Prognostic Value of Non-Coding RNA in Breast Cancer. Cancers. 2022; 14(12):2952. https://doi.org/10.3390/cancers14122952
Chicago/Turabian StyleSobhani, Navid, Richard Chahwan, Raheleh Roudi, Rachel Morris, Stefano Volinia, Dafei Chai, Alberto D’Angelo, and Daniele Generali. 2022. "Predictive and Prognostic Value of Non-Coding RNA in Breast Cancer" Cancers 14, no. 12: 2952. https://doi.org/10.3390/cancers14122952
Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
